Request Demo

Last update 04 Sep 2026

Bexobrutideg

Last update 04 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Proteolysis-targeting chimeras (PROTAC)

Synonyms

3-((4-(1-((1-(6-(((S)-2,6-Dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide, NX 5948, NX-5948

+ [1]

Target

BTK

Action

degraders

Mechanism

BTK degraders(Tyrosine-protein kinase BTK degraders)

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [6]

Active Indication

B-Cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+ [16]

Inactive Indication-

Originator Organization

Nurix Therapeutics, Inc.

Active Organization

Nurix Therapeutics, Inc.

Inactive Organization-

License Organization

Roche Holding AG

Nurix Therapeutics, Inc.

Drug Highest PhasePhase 3

First Approval Date-

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union)

Structure/Sequence

Molecular FormulaC42H54N12O5

InChIKeyHPTPDBYCFHFWJG-CWTKIQHKSA-N

CAS Registry2649400-34-8

Clinical Trials associated with Bexobrutideg

NCT07516093

/ RecruitingPhase 3

A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

Start Date03 Aug 2026

Sponsor / Collaborator

Nurix Therapeutics, Inc.

NCT07520006

/ RecruitingPhase 1/2

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Start Date01 Aug 2026

Sponsor / Collaborator

Nurix Therapeutics, Inc.

NCT07221500

/ RecruitingPhase 2

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.

Start Date15 Oct 2025

Sponsor / Collaborator

Nurix Therapeutics, Inc.

100 Clinical Results associated with Bexobrutideg

100 Translational Medicine associated with Bexobrutideg

100 Patents (Medical) associated with Bexobrutideg

Literatures (Medical) associated with Bexobrutideg

08 May 2025·JOURNAL OF MEDICINAL CHEMISTRY

In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical Space

Article

Author: Samuel Nash ; Magda Swedrowska ; Ken Grime ; Andy Pike ; Abhishek Srivastava

Established in vitro assays for ADME properties often struggle with compounds outside of the rule-of-5 space such as PROTACs. These bifunctional molecules, due to high lipophilicity and molecular weight, frequently exhibit low solubility, high nonspecific binding, and poor translation of assay data, necessitating empirical validation. This study evaluates the performance of standard ADME screening assays exemplified by 10 PROTACs in clinical development, with varying lipophilicity, in the context of the AstraZeneca data set. Assessment of in vitro metabolic clearance, plasma protein and incubation binding, blood-to-plasma ratio, Caco-2 permeability, and efflux was performed. Additionally, due to the poor performance of the aqueous solubility assay, the impact of biorelevant media was investigated on solubility. The primary objective was to evaluate the suitability of traditional ADME assays for PROTACs and understand the lipophilicity limits. This work aims to guide discovery teams on assay reliability and performance and inform decision-making regarding compound progression in this challenging area.

01 May 2025·AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Bruton Tyrosine Kinase Degraders

Review

Author: Sabakhtarishvili, Giorgi ; Tabbara, Imad A. ; Bajwa, Omer ; Alshebli, Mouza

Bruton tyrosine kinase (BTK) is a key enzyme involved in B-cell development and signaling, making it a crucial target in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance—both intrinsic and acquired—poses a significant challenge, often associated with BTK mutations like C481S. To address this, novel BTK degraders have been developed, leveraging proteolysis-targeting chimeras to selectively degrade both wild-type and mutant BTK forms. This approach offers a promising strategy to overcome BTKi resistance.Agents such as NRX-0492, BGB-16673, NX-5948, NX-2127, HZ-Q1060, ABBV-101, and AC676 have shown significant BTK degradation in preclinical and early clinical trials. NRX-0492 demonstrated over 90% BTK degradation with sustained pharmacodynamic effects, whereas BGB-16673 achieved clinical responses in 67% of patients with relapsed/refractory B-cell malignancies. Similarly, NX-5948 and NX-2127 showed potent BTK degradation, with NX-2127, in addition, targeting immunomodulatory proteins, resulting in partial and stable responses in chronic lymphocytic leukemia and non-Hodgkin lymphoma patients. HZ-Q1060, a preclinical candidate, displayed rapid and sustained BTK degradation in vivo. Early-phase trials of ABBV-101 and AC676 are also showing promising results.These BTK degraders have demonstrated favorable safety profiles, with manageable adverse events, and offer a novel therapeutic avenue for patients with BTKi-resistant malignancies. As clinical trials progress, these degraders hold the potential to significantly enhance treatment outcomes, offering a new frontier in personalized cancer therapy.

01 Mar 2025·BIOMEDICAL CHROMATOGRAPHY

A Validated Liquid Chromatography–Tandem Mass Spectrometry Assay for the Determination of NX‐5948 in Beagle Dog Plasma: Application to a Pharmacokinetic Study

Article

Author: Sun, Wenfei ; Wang, Fang ; Ma, Zheheng ; Chu, Furui

ABSTRACT:

Proteolysis targeting chimera (PROTAC) has been developed and currently enjoys widespread interest among the field of pharmaceutical manufacturing in recent decades. NX‐5948 is an orally active PROTAC Bruton tyrosine kinase degrader, which shows anti‐inflammatory and antitumor activities. In this study, a simple and fast bioanalytical method for the quantification of NX‐5948 in beagle dog plasma was developed using liquid chromatography–tandem mass spectrometry (LC‐MS/MS). A full method validation was performed according to regulatory guidelines. For the quantification, [M + H]+ was formed using an electrospray ionization (ESI) source in the positive ion mode, and selective reaction monitoring (SRM) was employed using a triple quadrupole mass spectrometry. The monitored precursor‐to‐product transitions were m/z 807.5 > 790.5 for NX‐5948 and m/z 812.4 > 452.1 for internal standard. A linear response was obtained at the concentration range of 0.5–200 ng/mL, with correlation coefficient > 0.99. The interday accuracy ranged from −9.03% to 5.99% (RSD < 7.84%), and the intraday accuracy from −5.15% to 8.56% (RSD < 6.90%). NX‐5948 was demonstrated to be stable under the present storage conditions. After validation, the method was successfully applied for the quantification of NX‐5948 in beagle dog plasma after oral and intravenous administration of the NX‐5948.

104

News (Medical) associated with Bexobrutideg

04 Sep 2026

·www.biospace.com

Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio

Through its DualityBio deal, Roche’s Genentech hopes to create antibody-drug conjugates with payloads that can circumvent growing cancer drug resistance. Just days after announcing a deal with a South Korean company, Roche’s Genentech is now partnering with Shanghai-based DualityBio to advance next-generation antibody-drug conjugates for cancer. Under the terms of the deal, Genentech will pay $45 million upfront and set aside up to more than $1 billion in development, regulatory and commercial milestones, according to a Friday morning news release from DualityBio. The biotech will also be eligible for tiered royalties on net sales of products that reach the market. At the heart of the partnership is DualityBio’s proprietary DUPAC platform, which generates payloads that go beyond the current cytotoxic payloads and thus help to address growing drug resistance, according to the company’s website. DUPAC payloads also have a short half-life, rapidly clearing from the body. DualityBio will use DUPAC to generate antibody-drug conjugate (ADC) programs against oncology targets of Genentech’s choosing, though the partners have yet to reveal specific disease priorities. The Chinese company will be in charge of discovery and early global development, with Genentech taking over after Phase 1a studies, according to the Friday announcement. Genentech already has two FDA-approved ADCs: Polivy, indicated for diffuse large B cell lymphoma, and Kadcyla, for the treatment of certain types of breast cancer. The DualityBio deal comes just days after Genentech put up to $2.3 billion on the line to work with South Korea’s Hanmi Pharm on a non-incretin peptide candidate designed to improve the quality of weight loss. Parent company Roche also inked a previous China deal in January, committing $570 million in upfront and near-term payments to MediLink for an ADC asset. Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass. DualityBio also continues the pharma’s dealing spree in cancer. In June, Roche linked up with Nurix Therapeutics in a deal that could reach $2.3 billion in value, gaining the right to co-develop and co-commercialize a BTK degrader candidate called bexobrutideg for B cell malignancies. In April, Roche deepened its relationship with C4 Therapeutics, betting more than $1 billion for two degrader-antibody conjugates for undisclosed cancer targets. The content above comes from the network. if any infringement, please contact us to modify.

ADCLicense out/in

01 Sep 2026

·www.globenewswire.com

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare ConferenceTuesday, September 8, 2026, at 3:00 p.m. ETH.C. Wainwright Healthcare ConferenceMonday, September 14, 2026, at 1:00 p.m. E.TBaird Healthcare ConferenceTuesday, September 15, 2026, at 3:10 p.m. ETMorgan Stanley Healthcare ConferenceWednesday, September 16, 2026, at 7:45 a.m. ET The fireside chats will be webcast live and may be accessed on the Investors section of the Nurix website, where they will be archived for 30 days after the event. About Nurix TherapeuticsNurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical stage oncology pipeline includes bexobrutideg, a degrader of Bruton’s tyrosine kinase (BTK), being co-developed in collaboration with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK-4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its wholly owned preclinical pipeline as well as those under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com. Forward-Looking StatementsThis press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s planned participation in the investor conferences described in this press release and the expected availability of live and archived webcasts. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to, changes to the timing, format or availability of the conferences and webcasts, as well as other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law. Contacts:Media & InvestorsKris FortnerNurix Therapeutics, Inc.kfortner@nurixtx.com

01 Sep 2026

·www.biospace.com

Nurix Therapeutics to Participate in Upcoming September 2026 Investor Conferences

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Tuesday, September 8, 2026, at 3:00 p.m. ET H.C. Wainwright Healthcare Conference Monday, September 14, 2026, at 1:00 p.m. E.T Baird Healthcare Conference Tuesday, September 15, 2026, at 3:10 p.m. ET Morgan Stanley Healthcare Conference Wednesday, September 16, 2026, at 7:45 a.m. ET The fireside chats will be webcast live and may be accessed on the Investors section of the Nurix website, where they will be archived for 30 days after the event. About Nurix Therapeutics Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical stage oncology pipeline includes bexobrutideg, a degrader of Bruton’s tyrosine kinase (BTK), being co-developed in collaboration with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK-4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its wholly owned preclinical pipeline as well as those under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit . Forward-Looking Statements This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding Nurix’s planned participation in the investor conferences described in this press release and the expected availability of live and archived webcasts. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to, changes to the timing, format or availability of the conferences and webcasts, as well as other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law. Contacts: Media & Investors Kris Fortner Nurix Therapeutics, Inc. kfortner@nurixtx.com

100 Deals associated with Bexobrutideg

External Link

KEGG	Wiki	ATC	Drug Bank
D13115	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Lymphoma	Phase 3	United States	Nurix Therapeutics, Inc.	03 Aug 2026
Chronic Lymphocytic Leukemia	Phase 3	United States	Nurix Therapeutics, Inc.	03 Aug 2026
Small Lymphocytic Lymphoma	Phase 3	United States	Nurix Therapeutics, Inc.	03 Aug 2026
Chronic lymphocytic leukaemia refractory	Phase 2	-	Nurix Therapeutics, Inc.	22 Oct 2025
Recurrent Chronic Lymphoid Leukemia	Phase 2	-	Nurix Therapeutics, Inc.	22 Oct 2025
Diffuse Large B-Cell Lymphoma	Phase 1	United States	Nurix Therapeutics, Inc.	13 Apr 2022
Diffuse Large B-Cell Lymphoma	Phase 1	France	Nurix Therapeutics, Inc.	13 Apr 2022
Diffuse Large B-Cell Lymphoma	Phase 1	Italy	Nurix Therapeutics, Inc.	13 Apr 2022
Diffuse Large B-Cell Lymphoma	Phase 1	Netherlands	Nurix Therapeutics, Inc.	13 Apr 2022
Diffuse Large B-Cell Lymphoma	Phase 1	Poland	Nurix Therapeutics, Inc.	13 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07221500 (DAYBREAK CLL-201, EHA2026)	Phase 2	Chronic Lymphocytic Leukemia \| Small Lymphocytic Lymphoma	100	Bexobrutideg 600 mg	hrlkemmyhg(ypkbtrdwen) = bauhcnlxgt nxumtffqsm (migmtoysdt ) View more	Positive	12 May 2026
NCT05131022 (NX-5948-301, EHA2026)	Phase 1	Chronic Lymphocytic Leukemia	142	Bexobrutideg (Ph1a dose-escalation)	lcdkhmckcf(wduesvjxei) = waayivecrt bmnhqeakzi (mjkkqobczb ) View more	Positive	12 May 2026
NCT05131022 (NX-5948-301, EHA2026)	Phase 1	Chronic Lymphocytic Leukemia	142	Bexobrutideg 600 mg (Ph1b C1 (BTKi/BCL2i exposed))	lcdkhmckcf(wduesvjxei) = tpqpgfeksk bmnhqeakzi (mjkkqobczb )	Positive	12 May 2026
NCT05131022 (NX-5948-301, EHA2025) Manual	Phase 1	Chronic Lymphocytic Leukemia	48	Bexobrutideg	awskcmgpfn(unjfghhfsg) = well tolerated nvodpxdadd (qyuiqlyrqx ) View more	Positive	14 May 2025
PS1883 (EHA2025)	Phase 1	Waldenstrom Macroglobulinemia MYD88 \| CXCR4	18	Bexobrutideg 600 mg	ywpxgycsnw(xpiaskbceq) = 27.8% dobuzetvzq (nhmwxtbels ) View more	Positive	14 May 2025
NCT05131022 (NX-5948-301, ASH2024) Manual	Phase 1	Chronic Lymphocytic Leukemia Last line \| Third line	34	NX-5948	eqwdensuex(rjvahujfhx) = Most common TEAEs were: purpura/contusion (44.1%, no Gr≥3); thrombocytopenia (23.5%, 2.9% Gr≥3); petechiae (29.4%, no Gr≥3); fatigue (20.6%, no Gr≥3); neutropenia (17.6%, 14.7% Gr≥3; pts with up to Gr 4 cytopenias were eligible for study participation); rash (23.5%, no Gr≥3, 2.9% SAE); headache (23.5%, no Gr≥3).There was no new onset atrial fibrillation/flutter or hypertension. fiqqfzapgk (oqlbowftjo ) View more	Positive	09 Dec 2024
NCT05131022 (GlobeNewswire) Manual	Phase 1	Waldenstrom Macroglobulinemia	79	NX-5948	qrphxgzrnj(haaqbyvyjq) = qonfugytxv nispijvrtv (kkurzxxrnv ) View more	Positive	19 Oct 2024
NCT05131022 (EHA 12024 \| EHA 22024) Manual	Phase 1	Chronic Lymphocytic Leukemia \| B-Cell Malignant Neoplasm	46	NX-5948	dpqimnista(fjmhpjqmln) = none yoxxcoslyq (facbtnzqhm ) View more	Positive	14 May 2024
NCT05131022 (Biospace) Manual	Phase 1	Chronic Lymphocytic Leukemia	7	NX-5948	kopawunkof(ftminzkucq) = kjbzvrjubo dnlobznswa (uhwoyxluck ) View more	Positive	16 Jan 2024
NCT05131022 (NX-5948-301, ASH2023) Manual	Phase 1	B-Cell Lymphoma Third line	14	NX-5948	alyifhqosh(utatgpdtlq) = jnugrymoyj dcxgumvtvh (bfzqxneykm ) View more	Positive	11 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis